Alnylam Pharmaceuticals is responsible for the funding and content of this website. The site is intended for UK patients for disease awareness purposes only. Nothing on the site constitutes individual medical advice. Individuals are advised to consult their physician or other appropriate HCP. PH1-TTR02-UK-00052 October 2021
You will be directed to a website for a medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).
Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.